| 马前锋,张 涛,薛玉刚,刘 蕾,王 磊.血清ANGPTL4、cTnI及mACEF评分与冠心病患者PCI术风险及术后临床结局的关系探究[J].现代生物医学进展英文版,2024,(15):2915-2919. |
| 血清ANGPTL4、cTnI及mACEF评分与冠心病患者PCI术风险及术后临床结局的关系探究 |
| Serum ANGPTL4, cTnI and mACEF Score and Patients with Coronary Heart Disease in PCI Risk and The Relationship between the Postoperative Clinical Outcome |
| Received:November 26, 2023 Revised:December 21, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.15.021 |
| 中文关键词: 冠心病 经皮冠状动脉介入术 血管生成素样蛋白4 心肌肌钙蛋白I mACEF评分 临床结局 |
| 英文关键词: Coronary heart disease Percutaneous coronary intervention Angiopoietin-like protein 4 Cardiac troponin I mACEF score Clinical outcome |
| 基金项目:陕西省重点研发计划项目（2019SF-189） |
|
| Hits: 81 |
| Download times: 55 |
| 中文摘要: |
| 摘要 目的：探究血清血管生成素样蛋白4（ANGPTL4）、心肌肌钙蛋白I（cTnI）及年龄、肌酐清除率、射血分数（mACEF）评分与冠心病患者经皮冠状动脉介入（PCI）术风险及术后临床结局的关系。方法：将自2020年1月至2022年10月在我院行行PCI术的108例冠心病患者纳入研究，根据欧洲心脏手术风险评估系统（EuroSCORE）Ⅱ评分评估PCI术风险，分为高危组和非高危组。所有患者术前均进行mACEF评分和EuroSCOREⅡ评分，检测血清ANGPTL4、cTnI表达水平；随访12个月，记录心血管不良事件发生情况；比较高危组与非高危组血清ANGPTL4、cTnI及mACEF评分，分析血清ANGPTL4、cTnI及mACEF评分与EuroSCOREⅡ评分的关系及对心血管不良事件的预测效能。结果：高危组血清ANGPTL4、cTnI水平及mACEF评分均高于非高危组（P＜0.05）；经Pearson相关性分析，冠心病患者血清ANGPTL4、cTnI水平及mACEF评分均与EuroSCOREⅡ评分呈正相关（P＜0.05）；在108例行PCI术的冠心病患者中，随访12个月期间，发生心血管不良事件20例，占18.52%；心血管不良事件组血清ANGPTL4、cTnI水平及mACEF评分均高于非心血管不良事件组（P＜0.05）；经多因素Logistic回归分析，血清ANGPTL4、cTnI水平及mACEF评分均是冠心病患者PCI术后心血管不良事件的独立影响因素（P＜0.05）；经ROC曲线分析，血清ANGPTL4、cTnI水平联合mACEF评分预测冠心病患者PCI术后心血管不良事件的敏感度为90.32%、特异度为52.37%、AUC为0.901。结论：血清ANGPTL4、cTnI及mACEF评分与冠心病患者PCI术风险密切相关，联合预测术后临床结局的效能较好。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the serum sample angiogenin protein 4 (ANGPTL4), cardiac troponin I (cTnI) and age, creatinine clearance, ejection fraction (mACEF) score and coronary heart disease patients with percutaneous coronary intervention (PCI) risk and the relationship between the postoperative clinical outcome. Methods: From January 2020 to October 2022 in our hospital fou PCI surgery of 108 cases of coronary heart disease patients into the study, according to the European cardiac surgery risk assessment system (EuroSCORE) Ⅱ score evaluation PCI perioperative risk, divided into high-risk groups and high-risk groups. All patients were performed preoperative mACEF score and EuroSCORE Ⅱ score, to detect serum ANGPTL4, cTnI expression level. Followed up for 12 months, the record of cardiovascular adverse events. Comparing high-risk group and the high-risk group of serum ANGPTL4, cTnI and mACEF score, analysis of serum ANGPTL4, cTnI and mACEF score and EuroSCORE Ⅱ grading and the relationship between the prediction of cardiovascular adverse events. Results: The high-risk group of serum ANGPTL4, cTnI levels and mACEF score were higher than in the high-risk group (P＜0.05). By the Pearson correlation analysis, patients with coronary heart disease ANGPTL4, cTnI levels and mACEF score and serum EuroSCORE Ⅱ scores were positively correlated (P＜0.05). Routine PCI surgery in patients with coronary heart disease in 108, during a follow-up of 12 months, 20 cases of adverse cardiovascular events, accounted for 18.52%. Cardiovascular adverse events group serum ANGPTL4, cTnI levels and mACEF score were higher than in non cardiovascular adverse events group (P＜0.05). After multiariable Logistic regression analysis, serum ANGPTL4, cTnI levels and mACEF score is PCI postoperative patients with coronary heart disease independent factors affecting cardiovascular adverse events (P＜0.05). ROC curve analysis showed that serum ANGPTL4 and cTnI levels combined with mACEF score were 90.32% sensitive, 52.37% specific and 0.901 AUC in predicting adverse cardiovascular events in patients with coronary heart disease after PCI. Conclusion: Serum ANGPTL4, cTnI and mACEF score is closely related to the risk of patients with coronary heart disease (CHD) in PCI, combined prediction of postoperative clinical outcome performance is better. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
